In the COG ACCL0431 whole-trial population, at the median 5.33‑year follow up, 18 children (29.5%) in the cisplatin with anhydrous sodium thiosulfate arm and 12 children (18.8%) in the cisplatin ...

Anhydrous sodium thiosulfate is recommended, within its marketing authorisation, for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised, ...

PEDMARK (Sodium Thiosulfate anhydrous) reduced the risk of CIO cases with non-metastatic solid tumors observed in Phase 3 studies (SIOPEL 6 & COG ACCL0431). We aimed to evaluate the investigational ...

Pedmarqsi® (anhydrous sodium thiosulfate) becomes the first and only treatment to be made available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in ...

Investigators from Children's Hospital Los Angeles and 37 other Children's Oncology Group hospitals in the U.S. and Canada have determined that sodium thiosulfate prevents cisplatin-induced ...

WASHINGTON — Sodium thiosulfate, administered before and after reperfusion for STEMI, did not improve infarct size between 4 months and 2 years compared with placebo, a speaker reported.The GIPS ...

Fennec Pharmaceuticals Inc. announced that the U.S. Patent and Trademark Office will issue U.S. Patent 10,792,363 entitled “Anhydrous Sodium Thiosulfate and Formulations Thereof.” RESEARCH TRIANGLE ...

Sodium thiosulfate showed no benefits for reducing injury to damaged areas of heart muscle following a heart attack, in a study presented at the American College of Cardiology’s 71st Annual ...

Sodium thiosulfate for the treatment of calciphylaxis is well studied in patients on hemodialysis but not in patients on peritoneal dialysis, Christy L. Gossett, NP, and colleagues from the Mayo ...